Cyclo Therapeutics Statistics Share Statistics Cyclo Therapeutics has 32.74M
shares outstanding. The number of shares has increased by 14.08%
in one year.
Shares Outstanding 32.74M Shares Change (YoY) 14.08% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 11.51M Failed to Deliver (FTD) Shares 274 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 434.13K, so 1.33% of the outstanding
shares have been sold short.
Short Interest 434.13K Short % of Shares Out 1.33% Short % of Float 1.51% Short Ratio (days to cover) 7.26
Valuation Ratios The PE ratio is -1.29 and the forward
PE ratio is -5.54.
Cyclo Therapeutics's PEG ratio is
0.04.
PE Ratio -1.29 Forward PE -5.54 PS Ratio 24.12 Forward PS 0.8 PB Ratio 5.46 P/FCF Ratio -1.6 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cyclo Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.45,
with a Debt / Equity ratio of 0.22.
Current Ratio 1.45 Quick Ratio 1.42 Debt / Equity 0.22 Debt / EBITDA -0.05 Debt / FCF -0.06 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $134.55K Profits Per Employee $-2.51M Employee Count 8 Asset Turnover 0.08 Inventory Turnover 0.39
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -40.5% in the
last 52 weeks. The beta is -0.57, so Cyclo Therapeutics's
price volatility has been lower than the market average.
Beta -0.57 52-Week Price Change -40.5% 50-Day Moving Average 0.79 200-Day Moving Average 0.85 Relative Strength Index (RSI) 47.9 Average Volume (20 Days) 1,761,627
Income Statement In the last 12 months, Cyclo Therapeutics had revenue of 1.08M
and earned -20.06M
in profits. Earnings per share was -1.23.
Revenue 1.08M Gross Profit 977.95K Operating Income -20.05M Net Income -20.06M EBITDA -20.03M EBIT -20.05M Earnings Per Share (EPS) -1.23
Full Income Statement Balance Sheet The company has 9.25M in cash and 1.03M in
debt, giving a net cash position of 8.21M.
Cash & Cash Equivalents 9.25M Total Debt 1.03M Net Cash 8.21M Retained Earnings -83.86M Total Assets 5.25M Working Capital -15.46M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -16.19M
and capital expenditures -2.42K, giving a free cash flow of -16.19M.
Operating Cash Flow -16.19M Capital Expenditures -2.42K Free Cash Flow -16.19M FCF Per Share -0.99
Full Cash Flow Statement Margins Gross margin is 90.85%, with operating and profit margins of -1862.69% and -1863.36%.
Gross Margin 90.85% Operating Margin -1862.69% Pretax Margin -1863.36% Profit Margin -1863.36% EBITDA Margin -1860.9% EBIT Margin -1862.69% FCF Margin -1503.84%
Dividends & Yields CYTH does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CYTH is $0.95,
which is 31.9% higher than the current price. The consensus rating is "Hold".
Price Target $0.95 Price Target Difference 31.9% Analyst Consensus Hold Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 9, 2020. It was a
backward
split with a ratio of 1:100.
Last Split Date Dec 9, 2020 Split Type backward Split Ratio 1:100
Scores Altman Z-Score -45.56 Piotroski F-Score 3
